S. Mahale

发表

Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.

M. Sutcliffe, Jean‐Didier Maréchal, S. Mahale, 2006, Bioorganic chemistry.

Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity.

S. Mahale, P. R. Jenkins, B. Chaudhuri, 2014, Journal of medicinal chemistry.

CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation.

M. Sutcliffe, Jean‐Didier Maréchal, S. Mahale, 2006, Bioorganic & medicinal chemistry letters.

Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization

S. Mahale, P. R. Jenkins, B. Chaudhuri, 2015, Cell Death and Disease.

Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.

Michael P. Dickens, A. J. Wilson, S. Mahale, 2009, Bioorganic & medicinal chemistry.

The design and synthesis of novel 3-[2-indol-1-yl-ethyl]-1H-indole derivatives as selective inhibitors of CDK4

M. Sutcliffe, Jean‐Didier Maréchal, S. Mahale, 2005 .

Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4.

S. Mahale, P. R. Jenkins, B. Chaudhuri, 2008, Bioorganic & medicinal chemistry.

Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors.

A. J. Wilson, S. Mahale, P. R. Jenkins, 2006, Organic & biomolecular chemistry.

Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation.

S. Mahale, V. Androutsopoulos, R. Arroo, 2009, Oncology reports.

Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.

M. Sutcliffe, Jean‐Didier Maréchal, A. J. Wilson, 2006, Organic & biomolecular chemistry.

New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.

M. Sutcliffe, Jean‐Didier Maréchal, S. Mahale, 2004, Chemical communications.

Development of CDK Inhibitors as Anticancer Agents: From Rational Design to CDK4-Specific Inhibition

S. Mahale, B. Chaudhuri, Sachin G. Mahale, 2006 .